Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,118 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of First-Line Osimertinib and Other EGFR-Tyrosine Kinase Inhibitors on Overall Survival in Untreated Advanced EGFR-Mutated Non-small Cell Lung Cancer in Japan: Updated Data from TREAD Project 01.
Hibino M, Imamura Y, Shimoyama R, Fukui T, Fukai R, Iwase A, Tamura Y, Chihara Y, Okabe T, Uryu K, Okuda T, Taguri M, Minami H. Hibino M, et al. Among authors: fukui t. Target Oncol. 2024 Nov;19(6):925-939. doi: 10.1007/s11523-024-01094-5. Epub 2024 Sep 20. Target Oncol. 2024. PMID: 39302602 Free PMC article.
Smoking History as a Predictor of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small Cell Lung Cancer Harboring EGFR Mutations.
Nishinarita N, Igawa S, Kasajima M, Kusuhara S, Harada S, Okuma Y, Sugita K, Ozawa T, Fukui T, Mitsufuji H, Yokoba M, Katagiri M, Kubota M, Sasaki J, Naoki K. Nishinarita N, et al. Among authors: fukui t. Oncology. 2018;95(2):109-115. doi: 10.1159/000488594. Epub 2018 Apr 26. Oncology. 2018. PMID: 29698957
Evaluation of concurrent chemoradiotherapy for locally advanced NSCLC according to EGFR mutation status.
Ishihara M, Igawa S, Sasaki J, Otani S, Fukui T, Ryuge S, Katono K, Hiyoshi Y, Kasajima M, Mitsufuji H, Kubota M, Yokoba M, Katagiri M, Sekiguchi A, Soda I, Ishiyama H, Hayakawa K, Masuda N. Ishihara M, et al. Among authors: fukui t. Oncol Lett. 2017 Jul;14(1):885-890. doi: 10.3892/ol.2017.6231. Epub 2017 May 23. Oncol Lett. 2017. PMID: 28693247 Free PMC article.
Efficacy of Platinum-Based Chemotherapy for Relapsed Small-Cell Lung Cancer after Amrubicin Monotherapy in Elderly Patients and Patients with Poor Performance Status.
Igawa S, Shirasawa M, Fukui T, Nishinarita N, Sone H, Ozawa T, Sugita K, Okuma Y, Kurahayashi S, Ono T, Sugimoto A, Mitsufuji H, Kubota M, Katagiri M, Sasaki J, Naoki K. Igawa S, et al. Among authors: fukui t. Oncology. 2018;94(4):207-214. doi: 10.1159/000486038. Epub 2018 Jan 31. Oncology. 2018. PMID: 29393275
EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan.
Takano T, Fukui T, Ohe Y, Tsuta K, Yamamoto S, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Furuta K, Tamura T. Takano T, et al. Among authors: fukui t. J Clin Oncol. 2008 Dec 1;26(34):5589-95. doi: 10.1200/JCO.2008.16.7254. Epub 2008 Sep 15. J Clin Oncol. 2008. PMID: 18794545
Impact of EGFR genotype on the efficacy of osimertinib in EGFR tyrosine kinase inhibitor-resistant patients with non-small cell lung cancer: a prospective observational study.
Igawa S, Ono T, Kasajima M, Ishihara M, Hiyoshi Y, Kusuhara S, Nishinarita N, Fukui T, Kubota M, Sasaki J, Hisashi M, Yokoba M, Katagiri M, Naoki K. Igawa S, et al. Among authors: fukui t. Cancer Manag Res. 2019 May 28;11:4883-4892. doi: 10.2147/CMAR.S207170. eCollection 2019. Cancer Manag Res. 2019. PMID: 31213907 Free PMC article.
Phase I and pharmacokinetic study of erlotinib administered in combination with amrubicin in patients with previously treated, advanced non-small cell lung cancer.
Otani S, Hamada A, Sasaki J, Wada M, Yamamoto M, Ryuge S, Takakura A, Fukui T, Yokoba M, Mitsufuji H, Toyooka I, Maki S, Kimura M, Hayashi N, Ishihara M, Kasajima M, Hiyoshi Y, Katono K, Asakuma M, Igawa S, Kubota M, Katagiri M, Saito H, Masuda N. Otani S, et al. Among authors: fukui t. Am J Clin Oncol. 2015 Aug;38(4):405-10. doi: 10.1097/COC.0b013e3182a2d98d. Am J Clin Oncol. 2015. PMID: 26214085 Clinical Trial.
Epidermal growth factor receptor mutation detection using high-resolution melting analysis predicts outcomes in patients with advanced non small cell lung cancer treated with gefitinib.
Takano T, Ohe Y, Tsuta K, Fukui T, Sakamoto H, Yoshida T, Tateishi U, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Matsuno Y, Furuta K, Tamura T. Takano T, et al. Among authors: fukui t. Clin Cancer Res. 2007 Sep 15;13(18 Pt 1):5385-90. doi: 10.1158/1078-0432.CCR-07-0627. Clin Cancer Res. 2007. PMID: 17875767
Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer.
Fukui T, Ohe Y, Tsuta K, Furuta K, Sakamoto H, Takano T, Nokihara H, Yamamoto N, Sekine I, Kunitoh H, Asamura H, Tsuchida T, Kaneko M, Kusumoto M, Yamamoto S, Yoshida T, Tamura T. Fukui T, et al. Clin Cancer Res. 2008 Aug 1;14(15):4751-7. doi: 10.1158/1078-0432.CCR-07-5207. Clin Cancer Res. 2008. PMID: 18676744
2,118 results